The treatment of patients with local stages I, II, IE, IIE of Hodgkin's lymphoma: medical radiological research center experience
https://doi.org/10.17650/1818-8346-2007-0-4-36-46
Abstract
In this article we present results of radiotherapy and combined modality treatment of 1882previously untreated patients with Hodgkin s lymphoma (HL) stages I, II, Ie, IIe at MRRC RAMS (Obninsk) between 1968 and 2006. Frequency and types of second malignancies, female fertility are presented too. 25-years overall survival rate was 59,1%, disease-specific survival — 73,2%, freedom from treatment failure — 46,8% after the radical program of radiotherapy. These rates in female patients with HL stages IA, IIA and histological subtype nodular sclerosis resulted 86,5%, 93,7%, 82,2% respectively. 20-years overall survival rate was 80,7%, disease-specific survival — 85,1%, freedom from treatment failure — 81,1% after combined modality treatment. In favorable prognosis group 36-month overall survival was 100% with no recurrences after 6 cycles of chemotherapy COPP followed by radiotherapy in total doses of20—24Gy. In intermediate prognosis group overall and disease-specific survival were 97,1%, freedom from treatment failure survival — 84,1% after 6—8 cycles ABVD followed by involved field radiotherapy in total doses 36Gy.
About the Authors
S. V. Shakhtarina
Medical Radiological research Center, RAMS
Russian Federation
Russian Federation
Obninsk
V. V. Pavlov
Medical Radiological research Center, RAMS
Russian Federation
Russian Federation
Obninsk
A. A. Danilenko
Medical Radiological research Center, RAMS
Russian Federation
Russian Federation
Obninsk
N. V. Afanasova
Medical Radiological research Center, RAMS
Russian Federation
Russian Federation
Obninsk
References
1. Kaplan H.S. Role of intensive radiation in the management of Hodgkin's disease. Cancer 1966;19:356-67.
2. Juweid M.E., Stroobants S., Hoekstra O.S. et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007;25(5): 571-8.
3. Павлов А.С., Лушина Л.И. Пятнадцатилетний опыт лучевой терапии по радикальной программе. В кн.: Диагностика илечение лимфом. Л.; 1981. с. 143-5.
4. Hoppe R.T. Stage I-II Hodgkin's disease: current therapeutic options and recommendations. Blood 1983;62(1):32-6.
5. Kaplan H.S., Rosenberg S.A. The management of the Hodgkin's disease. Cancer 1975;36:796-803.
6. Переслегин И.А., Филькова Е.М. Лимфогранулематоз. М., Медицина; 1980.
7. Байсоголов ГД., Хмелевская З.И. Актуальные вопросы лучевой терапии лимфогранулематоза. Мед радиол 1973;17(5):26-31.
8. Байсоголов ГД. Некоторые итоги и перспективы лечения лимфогранулематоза. Тер арх 1979;(6):39-43.
9. Tubiana M., Henry-Amar M., Hayat M. et al. Prognosis significance of the number of involved area in the early stages of Hodgkin's disease. Cancer 1984;54(5):885-94.
10. Nordentorf A.M., Nissen N.J., Jensen K.B. Experiences from the National Danish Hodgkin's Study Group (Lygra) with respect to diagnosis, classifications and treatment of Hodgkin's disease. Acta Radiol 1984;23:163-7.
11. Liao Z., Ha C.S., Vlachaki M.T. et al. Mantle irradiation alone for pathologic stage I and II Hodgkin's disease: long-term follow-up and patterns of failure. Int J Radiat Oncol Biol Phys 2001;50(4):971-7.
12. Jeliffe A.M. Hodgkin's disease: the pendulum swings. Knox lecture, Royal College of Radiologists. Clin Radiol 1979;30:121-37.
13. Hoppe R.T., Hanlon A., Hanks G. et al. Progress in treatment of Hodgkin's disease in the United States, 1973 versus 1983: the patterns of care study. Cancer 1994;74:3198-203.
14. Hoppe R.T. Radiation therapy in the management of Hodgkin's disease. Semin Oncol 1990;17(6):704-15.
15. Rosenberg S.A., Kaplan H.S. The management of stage I, II and III Hodgkin's disease with combined radiotherapy and chemotherapy. Cancer 1974;35:55-63.
16. Coltman C.A., Fuller L.M., Fisher R. Extended field radiotherapy versus involved field radiotherapy plus MOPP in stage I and II Hodgkin's disease. In: Adjuvant therapy of cancer. S.B. Jones, S.E. Salmon (eds). NY, Gruppe & Stratton; 1979.
17. Dubois B., Broquerie J.L., Pomgues H. et al. Les bounes precoses de la maladie de Hodgkin: analyse des causes d'echecs, attitudes therapeutiques. Bul Cancer 1981;68:19-24.
18. Hagemeister F., Fuller L., Velasquez W. et al. Stage I and II radiotherapy followed by six cycles of MOPP. Cancer Treat Rep 1982;66(4):789-98.
19. Radford J.A., Williams M.V., Hancock B.W. et al. Minimal initial chemotherapy plus involved field radiotherapy (RT) vs. mantle field RT for clinical stage IA/IIA supra-diaphragmatic Hodgkin's disease. Results of the UK Lymphoma Group LY07 trial. Haematology 2004;73(Suppl 65):32.
20. Bates N.P., Williams M.V., Bessel E.M. VBM ( vinblastine, bleomycin, methotrexate) chemotherapy with involved field radiotherapy in the management of “early” Hodgkin's disease. 7 th Ann Sci Meet Br Oncol Nord Cancer Soc Canterbury, 1992. Br J Cancer 1992;66(Suppl 17):1038.
21. Mauch P., Larson D., Osteen R. et al. Prognostic factors for positive surgical staging in patients with Hodgkin's disease. J Clin Oncol 1990;8(2):257-65.
22. Fuller L.M., Hagemeister F.B., North L.B. et al. The adjuvant role of two cycles of MOPP and low-dose lung irradiation in stage I through IIB Hodgkin's disease: preliminary results. Int J Radiat Oncol Biol Phys 1988;14:683-92.
23. Алиев Б.М., Васыгова Н.Ф., Иванова Е.М. и др. Пяти-десятилетние результаты лечения и отдаленные последствия лучевой терапии по радикальной программе больных ЛГМ I-II стадии. Вопр онкол 1984;(6):41-7.
24. Fuller L.M., Hagemeister F.B. Diagnosis and management of Hodgkin's disease in the adult. Cancer 1983;51(12):2469-76.
25. Rosenberg S.A. Report of the Committee on the staging of Hodgkin's disease. Cancer Res 1996;26:1340-8.
26. Carbone P.P., Kaplan H., Musshoff K. et al. Report of the Committee on Hodgkin's disease staging classification. Cancer 1971;31(11):1860-1.
27. Lister T.A., Growther D., Sutcliffe S.B. Report of the Committee convened to discuss the Evaluation and staging of patients with Hodgkin's disease: Cotswold's Meeting. J Clin Oncol 1989;7(11):1630-6.
28. Лучевая терапия лимфогранулематоза по радикальной программе. Методические рекомендации. Под ред. ГД. Байсоголова. М.; 1972.
29. Connors J.M., Klimo P. Is it an «Е» lesion or stage IV? An unsettled issue in Hodgkin's disease staging. J Clin Oncol 1984;2(12):1421-3.
30. Mauch P.M. Controversies in the management of early stage Hodgkin's disease. Blood 1994;83:319.
31. Musshoff K. Prognostic and therapeutic implications of staging in extranodal Hodgkin's disease. Cancer Res 1966;31:1814-971.
32. Horning S.J., Hoppe R.T., Kaplan H.S., Rosenberg S.A. Female reproductive potential after treatment for Hodgkin's disease. N Engl J Med 1981;304(23):1377-82.
33. Aisner J., Wiernik P.H., Pearl P. Pregnancy outcome in patients treated for Hodgkin's disease. J Clin Oncol 1993;11(3):507-12.
34. Swerdlow A.J., Jacobs P.A., Marks A. et al. Fertility, reproductive outcomes, and health of offsprings of patients treated for Hodgkin's disease: an investigation including chromosome examinations. Br J Cancer 1996;74(2):291-6.
35. Пылова И.В., Демина Е.А., Перилова Е.Е., Шмаков Р.Г. Беременность, роды и репродуктивная функция у женщин, больных лимфомой Ходжкина. Практ онкол 2007;8(2):102-8.
36. Байсоголов ГД., Шишкин И.П. Течение беременности и состояние родившихся детей у больных, леченных по поводу лимфогранулематоза. Мед радиол 1985;(5):35-7.
37. Franklin J., Pluetschow A., Paus M. et al. Second malignancy risk associated with treatment for Hodgkin's lymphoma: metaanalysis of the randomized trials. Ann Oncol 2006; doi: 10.1093/annonc/mdl302.
38. Cellai E., Magrini S.M., Masala G. et al. The risk of second malignant tumor and its consequences for the overall survival of Hodgkin's disease patients and the choice of their treatment at presentation: analysis of series of 1524cases consecutively treated at the Florence University Hospital. Int J Radiat Oncol Biol Phys 2001;49(5):1327-37.
39. Hancock S.L., Tucker M.A., Hoppe R.T. Breast cancer after treatment of Hodgkin's disease. J Natl Cancer Inst 1993;5(1):25-31.
40. Valagussa P., Santoro A., Fossati-Bellani F. et al. Second acute leukemia and other malignancies following treatment for Hodgkin's disease. J Clin Oncol 1986;4:830-7.
41. van Leeuwen F.E., Chorus A.M., van den Belt-Dusebout A.W et al. Leukemia risk following Hodgkin's disease: relation to cumulative dose of alkylating agents, treatment of teniposide combinations, number of episodes of chemotherapy, and bone marrow damage. J Clin Oncol 1994;12:1063-73.
42. Демина Е.А. Современные представления о лечении первичных больных лимфомой Ходжкина. Онкогематология. Media Medica; 2005. с. 104-12.
43. Hodgkin's disease. P.V. Mauch, J.O. Armitage, V. Diehl et al. (eds)/ Philadelphia; 1999.
44. Даценко П.В. Модифицированная программа лучевой терапии с поэтапным сокращением полей в рамках комплексного лечения лимфогранулематоза. http://vestnik.rncrr.ru/vestnik/v2/v2.htm.
Review
For citations:
Shakhtarina S.V., Pavlov V.V., Danilenko A.A., Afanasova N.V. The treatment of patients with local stages I, II, IE, IIE of Hodgkin's lymphoma: medical radiological research center experience. Oncohematology. 2007;(4):36-46. (In Russ.) https://doi.org/10.17650/1818-8346-2007-0-4-36-46
Views:
180
Email this article 